JLK

Company profile

About JLK

JLK Inc. is a pioneering medical AI company that develops comprehensive artificial intelligence solutions for medical imaging analysis, with particular expertise in neurological disorders and stroke management. Founded in 2014 and headquartered in Seoul, South Korea, JLK became the first company in the AI medical industry to list on the KOSDAQ exchange in December 2019. The company's flagship product, MEDIHUB STROKE, provides an end-to-end AI-based stroke management solution covering all clinical protocol steps from emergency room to rehabilitation for both hemorrhagic and ischemic stroke patients. JLK's technology analyzes multiple imaging modalities including CT, CTA, CTP, MRI, and MRA images. Beyond stroke, the company has expanded into chest X-ray analysis (JVIEWER-X), mammography screening (JBD-01K), prostate cancer detection, and dementia assessment. JLK has secured over 78 global medical AI licenses across major markets including FDA clearance in the United States, PMDA approval in Japan, CE certification in Europe, and MFDS approval in Korea. The company holds more than 96 core technology patents and has been designated for innovative medical device status in Korea. JLK also operates Hello Data, an AI medical data management platform that supports data processing for medical imaging, autonomous driving, and manufacturing industries. With subsidiaries in the United States (Silicon Valley), Japan (Tokyo), and a drug discovery subsidiary JLK BIO, the company serves health systems, hospitals, and medical institutions globally. JLK's mission is to accompany the journey of life with knowledge, driving innovation through AI technology to establish a new paradigm in medical diagnostics and healthcare delivery.

Company description · JLK official website